Maynard Um
-
-
-
-
-
-
-
Axsome Therapeutics (AXSM) PT Raised to $246 at Baird
-
-
-
-
-
-
-
Axsome Therapeutics (AXSM) Misses Q1 EPS by 43c
-
-
-
-
-
-
-
Piper Sandler on Axsome Therapeutics (AXSM): 'A High-Risk, High-Reward Opportunity'
-
-
-
-
-
-
-
RBC Capital Defending on Axsome Therapeutics (AXSM)
-
-
-
-
-
-
-
Axsome Therapeutics (AXSM) Tops Q4 EPS by 17c
-
-
-
-
-
-
-
Morgan Stanley Downgrades Axsome Therapeutics (AXSM) to Equalweight
-
-
-
-
-
-
-
Leerink on Axsome Therapeutics (AXSM): 'This is very positive news'
-
398,407 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

